November 8th 2016 TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has expanded distribution of the Senhance™ Surgical Robotic System (the "Senhance"). TransEnterix has partnered with Getz Healthcare to be the exclusive distribution partner for the Senhance in the Australian and New Zealand markets.
November 2nd 2016. Array Biopharma announced Q1 2016 results. Important business updates included binimetinib (NEMO program) submission (with Pierre Fabre) for marketing approval to European Medicines Agency (European equivalent of US FDA). With that, NEMO program currently is under review for marketing approval in both the U.S. and the E.U. which will help to launch the marketing process in those largest markets at the same time. Of the financial data notable was the company cash position as of October 3rd - $241M. With all current programs fully funded by partners, and any other major costly new programs very unlikely, Array Biopharma is not expected to bear any major expences in the foreseeable future and already has enough cash to commercialize NEMO program after its approval by US FDA.
September 26th 2016 Array Biopharma announced today that its COLUMBUS Phase 3 study ended successfully. The trial met its primary endpoint and showed average 14.9 months Progression Free Survival which is better than any of existing therapies and showed much less toxicity than any of existing therapies. That is a major milestone in the company development. Array Biopharma is looking forward to submitting the application to FDA next year.
September 7th 2016. Transenterix Inc announced that it changed their only product currently present on the market from ALF-X to Senhahce.